Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

OBJECTIVES: The aim of this study is to determine whether the ‘programmed’ infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Oba, Koji, Koike, Takao, Miyasaka, Nobuyuki, Mimori, Tsuneyo, Takeuchi, Tsutomu, Hirata, Shintaro, Tanaka, Eiichi, Yasuoka, Hidekata, Kaneko, Yuko, Murakami, Kosaku, Koga, Tomohiro, Nakano, Kazuhisa, Amano, Koichi, Ushio, Kazuyasu, Atsumi, Tatsuya, Inoo, Masayuki, Hatta, Kazuhiro, Mizuki, Shinichi, Nagaoka, Shouhei, Tsunoda, Shinichiro, Dobashi, Hiroaki, Horie, Nao, Sato, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937411/
https://www.ncbi.nlm.nih.gov/pubmed/31630117
http://dx.doi.org/10.1136/annrheumdis-2019-216169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937411/
https://www.ncbi.nlm.nih.gov/pubmed/31630117
http://dx.doi.org/10.1136/annrheumdis-2019-216169

Ejemplares similares